

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application No.	09/638,241
Filing Date	August 14, 2000
First Named Inventor	Ferree
Art Unit	3773
Examiner Name	Woo, Julian
Attorney Docket No.	026,314-018

Sheet

1

of

1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code (if known)				
	1.	WO	92/10982	07/09/1992	Pfizer Hospital Products Group		
	2.	WO	96/11642	04/25/1996	Raymedica, Inc.		
	3.	WO	99/05992	02/11/1999	Meadox Medicals. Inc.		
	4.	JP	5508795	12/09/1993			
	5.	JP	8098851	04/16/1996			
	6.	JP	7000430	01/06/1995			
	7.	JP	10507386	07/21/1998			

Examiner
Signature

2741369.1

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB-08a (08 03)

American LegalNet Inc.
www.USCourtForms.com

core will expand and contract in a desired fashion as it imbibes and expels fluids in response to various loads placed upon the spinal tract. The constraining jacket is porous to allow fluids to pass through to the hydrogel core, but prevents the hydrogel from escaping, thus fostering the natural physiology of the human intervertebral disc. By implanting two prosthetic spinal disc nucleus bodies side-by-side into a damaged disc of a human spine, both height and motion can be maintained.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

- ☐ A check in the amount of \$ _____ is enclosed for the above fee(s).
☐ Please charge \$ _____ to Deposit Account No. **50-2862** for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to O'Melveny and Myers' Deposit Account No. **50-2862**.

Respectfully submitted,

O'MELVENY & MYERS LLP

Dated: May 16, 2008

By: Diane K. Pang
Diane K. Pang
Reg. No. 54,550
Attorneys for Applicant

O'MELVENY & MYERS LLP
610 Newport Center Drive, 17th Floor
Newport Beach, CA 92660-6429
(949) 760-9600